Evolution of the data and methods in real-world COVID-19 vaccine effectiveness studies on mortality: a scoping review protocol

Loading...
Thumbnail Image
File version

Version of Record (VoR)

Author(s)
Stehlik, Paulina
Dowsett, Caroline
Camacho, Ximena
Falster, Michael O
Lim, Renly
Nasreen, Sharifa
Pratt, Nicole L
Pearson, Sallie-Anne
Henry, David
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2024
Size
File type(s)
Location
Abstract

Background Early evidence on COVID-19 vaccine efficacy came from randomised trials. Many important questions subsequently about vaccine effectiveness (VE) have been addressed using real-world studies (RWS) and have informed most vaccination policies globally. As the questions about VE have evolved during the pandemic so have data, study design, and analytical choices. This scoping review aims to characterise this evolution and provide insights for future pandemic planning - specifically, what kinds of questions are asked at different stages of a pandemic, and what data infrastructure and methods are used? Methods and analysis We will identify relevant studies in the Johns Hopkins Bloomberg School of Public Health VIEW-hub database, which curates both published and preprint VE RWS identified from PubMed, Embase, Scopus, Web of Science, the WHO COVID Database, MMWR, Eurosurveillance, medRxiv, bioRxiv, SSRN, Europe PMC, Research Square, Knowledge Hub, and Google. We will include RWS of COVID-19 VE that reported COVID-19-specific or all-cause mortality (coded as 'death' in the 'effectiveness studies' data set). Information on study characteristics; study context; data sources; design and analytic methods that address confounding will be extracted by single reviewer and checked for accuracy and discussed in a small group setting by methodological and analytic experts. A timeline mapping approach will be used to capture the evolution of this body of literature. By describing the evolution of RWS of VE through the COVID-19 pandemic, we will help identify options for VE studies and inform policy makers on the minimal data and analytic infrastructure needed to support rapid RWS of VE in future pandemics and of healthcare strategies more broadly. Ethics and dissemination As data is in the public domain, ethical approval is not required. Findings of this study will be disseminated through peer-reviewed publications, conference presentations, and working-papers to policy makers. Registration https://doi.org/10.17605/OSF.IO/ZHDKR

Journal Title

BMJ Open

Conference Title
Book Title
Edition
Volume

14

Issue

3

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement

© Author(s) (or their employer(s)) 2024. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

Item Access Status
Note
Access the data
Related item(s)
Subject
Persistent link to this record
Citation

Stehlik, P; Dowsett, C; Camacho, X; Falster, MO; Lim, R; Nasreen, S; Pratt, NL; Pearson, S-A; Henry, D, Evolution of the data and methods in real-world COVID-19 vaccine effectiveness studies on mortality: a scoping review protocol, BMJ Open, 2024, 14 (3), pp. e079071

Collections